Director at the Mayo Clinic and Mayo Clinic Laboratories In Rochester, Minnesota; Associate Professor of Medicine and Laboratory Medicine, Mayo Clinic College of Medicine and Science
On December 8th, 2021 the CDC released new recommendations for preexposure prophylaxis (PrEP) for the prevention of HIV infection in the US. These new guidelines include important updates designed to help increase access to and awareness of PrEP as well as new recommendations for laboratory testing. This webinar will review these important changes and discuss how they will impact patients, clinicians, and the clinical laboratories providing results that play a critical role in this updated approach.
Learning Objectives
Outline current HIV/PrEP landscape in the US
Describe important changes in the new 2021 CDC PrEP Guidelines
Review rationale of new recommendations for NAAT in PrEP monitoring and potential impact on clinical laboratories, clinicians, and patients
Webinars will be available for unlimited on-demand viewing after live event.
The implementation of a preemptive pharmacogenomics (PGx) program in a hospital setting requires a multidisciplinary approach to ensure seamless integration of each stage of the process for...
The implementation of a preemptive pharmacogenomics (PGx) program in a hospital setting requires a multidisciplinary approach to ensure seamless integration of each stage of the process for...
Dynamic changes in chromatin drive gene expression programs during cellular development and contribute to pathological changes underlying disease. To date, efforts to characterize chromatin...
Ever wonder what you’re missing in your data? The sheer complexity of today’s flow and mass cytometry datasets demands automated solutions. Machine learning plugins only provide...
Tumor genomic profiling can be complicated, especially for diseases that commonly have multiple different genomic biomarkers of interest, such as non-small cell lung cancer (NSCLC) and color...